Amphastar Pharmaceuticals opened higher at $28.77, compared with its previous close of $28.60. In the last trading session, the stock traded between $28.53 and $29.02. It showed an upward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Amphastar Pharmaceuticals is now worth
$ 136.28
Giving a profit of
$ 36.28 (36.28%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 3 Analysts
Buy
0%
Hold
66.67%
Sell
33.33%
Markets Today
Today's Change
+$0.27 (+0.93%)
Day High
$29.02
Day Low
$28.53
Day Open
$28.77
Prev Close
$28.60
Volume
2,87,933
1W Return
3.03%
1M Return
7.86%
3M Return
41.25%
6M Return
56.45%
1Y Return
6.28%
Fundamentals
Market Cap ($ Mn)
1,231
PE Ratio
13.02
PB Ratio
1.22
PEG Ratio
0.25
ROE
12.88%
ROCE
9.75%
EPS (TTM)
$0.89
Investment Returns
1 Week
3.03%
1 Month
7.86%
3 Months
41.25%
6 Months
56.45%
9 Months
0.96%
Financials
Quarterly
All values in $ Mn
174.4
Jun 25
191.8
Sep 25
183.1
Dec 25
171.2
Mar 26
183.9
Jun 26
207.6
Sep 26
Updates
11Nov
Amphastar Pharmaceuticals to present at Jefferies Healthcare Conference
Amphastar Pharmaceuticals will present at the Jefferies Global Healthcare Conference in London. CFO Bill Peters and EVP Jacob Liawatidewi are scheduled to speak on November 18, 2026. The fireside chat begins at 12:00 pm GMT and will be webcast for public access. Webcast availability extends for 30 days after the live presentation concludes.
Yesterday
6Nov
Wells Fargo raises Amphastar Pharmaceuticals price target to $25
Wells Fargo raised Amphastar Pharmaceuticals' price target from $20 to $25. Analyst Benjamin Burnett maintained an Equal-Weight rating on the stock. The revision represents a $5 increase in the projected share value.
6 days ago
8Jul
Amphastar unit receives FDA warning letter for CGMP violations
International Medication Systems, an Amphastar Pharmaceuticals subsidiary, received an FDA warning letter on July 2, 2026, citing CGMP violations at its California facility following a December 2025 inspection. The letter identifies issues with investigation procedures, environmental monitoring, and equipment. IMS continues operations while implementing a remediation plan, though further regulatory action remains possible.
4mo ago
16Jun
FDA approves OTC naloxone spray Rextovy to combat opioid overdoses
The FDA approved Rextovy, a 4 mg naloxone nasal spray, for OTC use to treat opioid overdoses, expanding access to life-saving medication. Overdose deaths have decreased since 2023, but synthetic opioids remain a concern. The product includes clear usage instructions and is safe even without confirmed opioid presence.
